

**Neuland Laboratories Limited**  
11th floor (5th level), Phoenix IVY Building,  
Plot No.573A-III, Road No.82, Jubilee Hills,  
Hyderabad-500033, Telangana, India.



CONTACT  
040 6761 1600 / 6761 1700  
neuland@neulandlabs.com  
neulandlabs.com

April 20, 2026

To

**BSE Limited**  
Phiroze Jeejeebhoy Towers,  
25<sup>th</sup> Floor, Dalal Street,  
Mumbai – 400 001

**The National Stock Exchange of India Ltd**  
Exchange Plaza,  
Bandra Kurla Complex  
Bandra (E), Mumbai – 400 001

**Scrip Code: 524558**

**Scrip Code: NEULANDLAB; Series: EQ**

Dear Sir/Madam,

**Sub: Notice of Board Meeting**

Pursuant to Regulation 29 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby inform you that a meeting of Board of Directors of the Company is scheduled to be held on Tuesday, May 12, 2026, *inter-alia*, to:

- a. Consider and approve the Audited Standalone and Consolidated Financial Results of the Company for the quarter and financial year ended March 31, 2026; and
- b. Recommend final dividend, if any, for the financial year 2025-26.

In continuation to our letter dated March 23, 2026, pursuant to the Company's Insider Trading Code, the trading window for dealing in the equity shares of the Company shall continue to remain closed from April 1, 2026 till 48 hours after the declaration of audited financial results of the Company for the quarter and financial year ended March 31, 2026 and final dividend, if any, for the financial year 2025-26 to the stock exchanges.

This is for your information and records.

Yours sincerely,  
For **Neuland Laboratories Limited**

**Sarada Bhamidipati**  
**Company Secretary**